{"title":"导航医疗器械安全:现状、挑战和未来监管方向。","authors":"Omar Aimer, Catherine Baldridge","doi":"10.1007/s40264-025-01599-6","DOIUrl":null,"url":null,"abstract":"<p><p>Medical devices are indispensable in modern healthcare. They enable the prevention, diagnosis, and treatment of diseases while enhancing patient outcomes. However, the increasing complexity of these devices, particularly those incorporating advanced technologies such as artificial intelligence (AI) introduces new challenges to their safe use. The vulnerabilities of medical devices can lead to adverse events ranging from minor complications to severe injuries or fatalities, and there is an increasing health risk to those devices that are interconnected to electronic health management systems and internet protocols. Despite efforts by regulatory authorities such as the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and Health Canada, disparities in reporting systems and monitoring practices persist globally, hindering effective safety oversight. This paper explores the current landscape of medical device safety, focusing on regulatory frameworks, reporting systems, and the challenges posed by fragmented data collection and underreporting. It highlights the critical role of postmarket surveillance (PMS) in identifying risks and ensuring device performance in real-world settings. The integration of emerging technologies, such as AI for predictive safety and blockchain for traceability, offers promising solutions to enhance monitoring and mitigate risks early in the device lifecycle. In addition, the paper examines harmonization efforts led by organizations such as The International Medical Device Regulators Forum (IMDRF), the International Society of Pharmacovigilance (ISoP) and the World Health Organazition (WHO), which aim to standardize reporting practices and improve global collaboration. Key recommendations include leveraging real-world data, enhancing cybersecurity measures, and fostering international cooperation to streamline regulatory processes. By addressing these challenges and embracing innovation, stakeholders can ensure that medical devices continue to advance healthcare while maintaining the highest safety standards. Such collective efforts are essential for safeguarding patient trust and improving global health outcomes.</p>","PeriodicalId":11382,"journal":{"name":"Drug Safety","volume":" ","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Navigating Medical Device Safety: Current Status, Challenges, and Future Regulatory Directions.\",\"authors\":\"Omar Aimer, Catherine Baldridge\",\"doi\":\"10.1007/s40264-025-01599-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Medical devices are indispensable in modern healthcare. They enable the prevention, diagnosis, and treatment of diseases while enhancing patient outcomes. However, the increasing complexity of these devices, particularly those incorporating advanced technologies such as artificial intelligence (AI) introduces new challenges to their safe use. The vulnerabilities of medical devices can lead to adverse events ranging from minor complications to severe injuries or fatalities, and there is an increasing health risk to those devices that are interconnected to electronic health management systems and internet protocols. Despite efforts by regulatory authorities such as the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and Health Canada, disparities in reporting systems and monitoring practices persist globally, hindering effective safety oversight. This paper explores the current landscape of medical device safety, focusing on regulatory frameworks, reporting systems, and the challenges posed by fragmented data collection and underreporting. It highlights the critical role of postmarket surveillance (PMS) in identifying risks and ensuring device performance in real-world settings. The integration of emerging technologies, such as AI for predictive safety and blockchain for traceability, offers promising solutions to enhance monitoring and mitigate risks early in the device lifecycle. In addition, the paper examines harmonization efforts led by organizations such as The International Medical Device Regulators Forum (IMDRF), the International Society of Pharmacovigilance (ISoP) and the World Health Organazition (WHO), which aim to standardize reporting practices and improve global collaboration. Key recommendations include leveraging real-world data, enhancing cybersecurity measures, and fostering international cooperation to streamline regulatory processes. By addressing these challenges and embracing innovation, stakeholders can ensure that medical devices continue to advance healthcare while maintaining the highest safety standards. Such collective efforts are essential for safeguarding patient trust and improving global health outcomes.</p>\",\"PeriodicalId\":11382,\"journal\":{\"name\":\"Drug Safety\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2025-08-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Safety\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s40264-025-01599-6\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40264-025-01599-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Navigating Medical Device Safety: Current Status, Challenges, and Future Regulatory Directions.
Medical devices are indispensable in modern healthcare. They enable the prevention, diagnosis, and treatment of diseases while enhancing patient outcomes. However, the increasing complexity of these devices, particularly those incorporating advanced technologies such as artificial intelligence (AI) introduces new challenges to their safe use. The vulnerabilities of medical devices can lead to adverse events ranging from minor complications to severe injuries or fatalities, and there is an increasing health risk to those devices that are interconnected to electronic health management systems and internet protocols. Despite efforts by regulatory authorities such as the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and Health Canada, disparities in reporting systems and monitoring practices persist globally, hindering effective safety oversight. This paper explores the current landscape of medical device safety, focusing on regulatory frameworks, reporting systems, and the challenges posed by fragmented data collection and underreporting. It highlights the critical role of postmarket surveillance (PMS) in identifying risks and ensuring device performance in real-world settings. The integration of emerging technologies, such as AI for predictive safety and blockchain for traceability, offers promising solutions to enhance monitoring and mitigate risks early in the device lifecycle. In addition, the paper examines harmonization efforts led by organizations such as The International Medical Device Regulators Forum (IMDRF), the International Society of Pharmacovigilance (ISoP) and the World Health Organazition (WHO), which aim to standardize reporting practices and improve global collaboration. Key recommendations include leveraging real-world data, enhancing cybersecurity measures, and fostering international cooperation to streamline regulatory processes. By addressing these challenges and embracing innovation, stakeholders can ensure that medical devices continue to advance healthcare while maintaining the highest safety standards. Such collective efforts are essential for safeguarding patient trust and improving global health outcomes.
期刊介绍:
Drug Safety is the official journal of the International Society of Pharmacovigilance. The journal includes:
Overviews of contentious or emerging issues.
Comprehensive narrative reviews that provide an authoritative source of information on epidemiology, clinical features, prevention and management of adverse effects of individual drugs and drug classes.
In-depth benefit-risk assessment of adverse effect and efficacy data for a drug in a defined therapeutic area.
Systematic reviews (with or without meta-analyses) that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement.
Original research articles reporting the results of well-designed studies in disciplines such as pharmacoepidemiology, pharmacovigilance, pharmacology and toxicology, and pharmacogenomics.
Editorials and commentaries on topical issues.
Additional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in Drug Safety Drugs may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand important medical advances.